Company Filing History:
Years Active: 2023
Title: Innovator Spotlight: Kristian Hobolt-Jensen
Introduction
Kristian Hobolt-Jensen, based in Penzberg, Germany, is an accomplished inventor with a specific focus on innovative therapeutic solutions. He has made significant contributions to the field of biochemistry, particularly in the development of antibodies that have important implications for medical treatment.
Latest Patents
Hobolt-Jensen holds a patent for an "Antibody that binds to VEGF-A and ANG2 and methods of use." This patent relates to anti-VEGF-A/anti-ANG2 antibodies, specifically in the form of a bispecific Fab fragment, and outlines various methods of using these innovative antibodies in therapeutic applications.
Career Highlights
Currently, Kristian Hobolt-Jensen is employed by Hoffmann-La Roche Inc., a leading global healthcare company that operates in the research and development of pharmaceuticals. His work at the company emphasizes the importance of novel antibody therapies in treating various diseases.
Collaborations
Throughout his career, Hobolt-Jensen has collaborated with notable colleagues, including Roland Beckmann and Sebastian Fenn. These partnerships enhance the research output and accelerate the progress of innovative solutions in the field.
Conclusion
Kristian Hobolt-Jensen stands out as a dedicated inventor in the biotechnology sector, with his groundbreaking patent contributing to advancements in medical therapies. His collaboration with prominent professionals and his role at Hoffmann-La Roche Inc. underline his commitment to innovation and improving health outcomes.